Chagas Disease (American Trypanosomiasis) Drug pipeline Report 2020- Current Status, Phase, Mechanism, Route of Administration, Companies, and Clinical Trials of Pre-clinical and Clinical Drugs

October 2019 | 70 pages | ID: C3DB52D4CA3EEN
VPAResearch

Abstracts

Chagas Disease (American Trypanosomiasis) Drug pipeline report- 2020 is an annual R&D review of Chagas Disease (American Trypanosomiasis) pipeline candidates. The report presents the current status of all major Chagas Disease (American Trypanosomiasis) therapeutic compounds. Detailed insights into Chagas Disease (American Trypanosomiasis) pipeline development, current status, companies, drug profiles and Chagas Disease (American Trypanosomiasis) preclinical and clinical trials are included.

2020 Chagas Disease (American Trypanosomiasis) Pipeline Market Insights
Chagas Disease (American Trypanosomiasis) disease overview, 2020 pipeline review, insights into leading companies, dominant mechanism of action, majority of administration route of Chagas Disease (American Trypanosomiasis) therapies, pipeline by phase and others are included.

Chagas Disease (American Trypanosomiasis) pipeline Drug profiles-
Active and inactive drug profiles covering information including drug name/synonym, sponsor/collaborators/Developer/originator, drug mechanism, route of administration, orphan drug status, NME, phase, development status, and others are included.

Chagas Disease (American Trypanosomiasis) Therapeutic Drug candidates
Both active and inactive Chagas Disease (American Trypanosomiasis) pipeline drug candidates are included in the report

Chagas Disease (American Trypanosomiasis) Clinical Trials and preclinical Studies
Chagas Disease (American Trypanosomiasis) In-vitro and In-vivo studies, discovery stage and pre-clinical stage trial details, Clinical trial titles, duration, location, phase, sponsors, and other details are provided.

Chagas Disease (American Trypanosomiasis) pipeline market developments
Chagas Disease (American Trypanosomiasis) Pipeline market news and deals including mergers, acquisitions, approvals, collaborations, trial initiations, results, investments, licensing opportunities and others are provided.

Chagas Disease (American Trypanosomiasis) pipeline companies in active development
The report analyzes Chagas Disease (American Trypanosomiasis) pipeline of the below companies-

Astellas Pharma, AstraZeneca Plc, Bayer AG, Collaborations Pharmaceuticals, Daiichi Sankyo Co Ltd, Drugs for Neglected Diseases initiative, Eisai Co Ltd, Evotec AG, GlaxoSmithKline Plc, Kancera AB, Novartis AG, Oblita Therapeutics BVBA, RIKEN, Sanofi

Report Coverage

What to look out for in 2020
Drugs moving from early stage to mid-to-late stages and drugs to look after in 2020 are included

Pipeline Snapshot
Pipeline candidate count - Drug by phase, mechanism of action, route of administration, designation and others

Companies
14 Companies investing in Chagas Disease (American Trypanosomiasis) pipeline from discovery stage to pre-registration phase are included

Drug profiles
Over 10 details of each Chagas Disease (American Trypanosomiasis) pipeline candidate are included

Company Profiles
Business overview and contact details of all companies operating in the industry are provided

Market Developments
News, Developments and other recent industry developments are included

Contents

1. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE MARKET INSIGHTS, 2020

1.1 Chagas Disease (American Trypanosomiasis) Disease Overview
1.2 Chagas Disease (American Trypanosomiasis) Drug Pipeline Snapshot, 2020
  1.2.1 Chagas Disease (American Trypanosomiasis) Pipeline Drugs by Phase
  1.2.2 Chagas Disease (American Trypanosomiasis) Pipeline Drugs by Company
  1.2.3 Chagas Disease (American Trypanosomiasis) Pipeline Drugs by Mechanism of Action
  1.2.4 Chagas Disease (American Trypanosomiasis) Pipeline Drugs by Route of Administration

2. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) COMPANY WISE PIPELINE DETAILS

Astellas Pharma Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
AstraZeneca Plc Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Bayer AG Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Collaborations Pharmaceuticals Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Daiichi Sankyo Co Ltd Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Drugs for Neglected Diseases initiative Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Eisai Co Ltd Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Evotec AG Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
GlaxoSmithKline Plc Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Kancera AB Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Novartis AG Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Oblita Therapeutics BVBA Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
RIKEN Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details
Sanofi Chagas Disease (American Trypanosomiasis) Pipeline Drugs
  Company Profile
  Drug Candidate Details

3. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) DRUG PIPELINE PROFILES

3.1 Discovery and Preclinical Drug Profiles
3.2 Phase 1 Drug Profiles
3.3 Phase 2 Drug Profiles
3.4 Phase 3 Drug Profiles

4. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS) PIPELINE NEWS AND DEVELOPMENTS

5. APPENDIX

5.1 Primary and Secondary Research Methodology
5.2 Publisher Expertize
5.3 Contacts